ATRA · Nasdaq · ·
Next earnings: November 11, 2026
$8.08-3.7%Sep 29 close
Atara Biotherapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $630K | $17.6M | -96.42% |
| Profit | -$4.8M | $2.4M | -302.51% |
| Profit per share | -$0.32 | $0.19 | -268.42% |
| Free Cash Flow | -$5.7M | -$24.6M | +76.80% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the FDA where we confirmed the opportunity to resubmit the tabelecleucel BLA based on the existing Phase 3 single arm ALLELE trial. We are actively working with and supporting PFP in a resubmission that includes an updated dataset with additional patients and longer follow-up. Patients are still dying from EBV-driven PTLD, and we remain fully committed to ensuring that they have access to this new medicine,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Atara Biotherapeutics, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Atara Biotherapeutics, Inc. has no earnings call transcript available.